Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has been assigned an average rating of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $27.40.

A number of brokerages have weighed in on ITCI. SunTrust Banks restated a “hold” rating and issued a $22.00 target price (up previously from $16.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. ValuEngine upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Leerink Swann restated a “market perform” rating and issued a $12.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, August 15th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, August 15th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a research report on Thursday, August 10th.

Shares of Intra-Cellular Therapies (NASDAQ ITCI) traded up $0.42 during trading hours on Thursday, reaching $15.09. 468,836 shares of the company were exchanged, compared to its average volume of 679,582. Intra-Cellular Therapies has a fifty-two week low of $7.85 and a fifty-two week high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.53). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The firm’s quarterly revenue was up 675.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.70) earnings per share. equities analysts anticipate that Intra-Cellular Therapies will post -2.16 EPS for the current fiscal year.

In other Intra-Cellular Therapies news, major shareholder Alafi Capital Co Llc purchased 258,065 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were bought at an average price of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the acquisition, the insider now owns 3,953,270 shares in the company, valued at $61,275,685. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher D. Alafi purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were acquired at an average price of $15.55 per share, for a total transaction of $155,500.00. Following the acquisition, the director now owns 744,466 shares of the company’s stock, valued at approximately $11,576,446.30. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Intra-Cellular Therapies by 336.1% during the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after purchasing an additional 447,586 shares during the period. Swiss National Bank lifted its holdings in Intra-Cellular Therapies by 31.0% in the third quarter. Swiss National Bank now owns 69,800 shares of the biopharmaceutical company’s stock valued at $1,101,000 after buying an additional 16,500 shares during the period. Fox Run Management L.L.C. acquired a new position in Intra-Cellular Therapies in the third quarter valued at $390,000. First Midwest Bank Trust Division lifted its holdings in Intra-Cellular Therapies by 18.2% in the third quarter. First Midwest Bank Trust Division now owns 184,836 shares of the biopharmaceutical company’s stock valued at $2,917,000 after buying an additional 28,487 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Intra-Cellular Therapies by 192.2% in the first quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 81,969 shares during the period. Institutional investors own 74.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/intra-cellular-therapies-inc-itci-receives-consensus-recommendation-of-buy-from-analysts.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.